Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Bhaswati Mukherjee"'
Autor:
Ernesto Luna, Pankaj Agrawal, Riyaz Mehta, Maria E Boone, Charlotte Vernhes, Colombe Denys, Robert Small, Bhaswati Mukherjee, Norbert Tennagels, Stefan Maerten, Donald R Drake
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0197478 (2018)
BACKGROUND:The manufacture of insulin analogs requires sophisticated production procedures which can lead to differences in the structure, purity, and/or other physiochemical properties of resultant products that can affect their biologic activity. H
Externí odkaz:
https://doaj.org/article/34712a32711f422d908727950df8b791
Autor:
Mandy Mohnicke, Arnd Blecher, Kathrin Beichert, Bernd Bidlingmaier, Ernst-Josef Todt, Christoph Dette, Baerbel Rotthaeuser, Bhaswati Mukherjee
Publikováno v:
Journal of Pharmaceutical Sciences. 112:963-973
Autor:
Tadej Battelino, Thomas Danne, Steve V. Edelman, Pratik Choudhary, Eric Renard, Jukka Westerbacka, Bhaswati Mukherjee, Valerie Pilorget, Mathieu Coudert, Richard M. Bergenstal
Publikováno v:
Diabetes, Obesity and Metabolism. 25:545-555
Autor:
Bhaswati Mukherjee
Publikováno v:
Journal of Indian Ocean Studies. 30:55-59
Autor:
S. R. Aravind, Kiran P. Singh, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
Publikováno v:
Diabetes Therapy. 13:1299-1310
We compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (70% intermediate SAR341402 protamine and 30% rapid SAR341402 solution) (SARThis phase 3, randomized, open-label, multinational, 26-week tria
Autor:
Tadej, Battelino, Thomas, Danne, Steve V, Edelman, Pratik, Choudhary, Eric, Renard, Jukka, Westerbacka, Bhaswati, Mukherjee, Valerie, Pilorget, Mathieu, Coudert, Richard M, Bergenstal
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 25(2)
To use continuous glucose monitoring (CGM)-based time-in-range (TIR) as a primary efficacy endpoint to compare the second-generation basal insulin (BI) analogues insulin glargine 300 U/ml (Gla-300) and insulin degludec 100 U/ml (IDeg-100) in adults w
Autor:
Mandy, Mohnicke, Arnd, Blecher, Kathrin, Beichert, Bernd, Bidlingmaier, Ernst-Josef, Todt, Christoph, Dette, Baerbel, Rotthaeuser, Bhaswati, Mukherjee
Publikováno v:
Journal of pharmaceutical sciences.
SAR341402 (Insulin aspart Sanofi®) is an insulin aspart biosimilar that can be used for continuous subcutaneous insulin infusion (CSII) in pump systems. The physicochemical stability of SAR341402 for CSII use was evaluated in several in vitro experi
Autor:
RICHARD M. BERGENSTAL, STEVEN EDELMAN, PRATIK CHOUDHARY, THOMAS DANNE, ERIC RENARD, JUKKA WESTERBACKA, BHASWATI MUKHERJEE, PASCALINE PICARD, VALERIE PILORGET, TADEJ BATTELINO
Publikováno v:
Diabetes. 71
Background: InRange has previously demonstrated that insulin glargine 300 U/mL (Gla-300) is non-inferior to insulin degludec 100 U/mL (IDeg-100) in terms of time in glucose range 70--180 mg/dL (primary endpoint) and total glucose coefficient of varia
Autor:
Viswanathan, Mohan, Wolfgang, Schmider, Kiran P, Singh, Baerbel, Rotthaeuser, Bhaswati, Mukherjee, S R, Aravind
Publikováno v:
Indian journal of endocrinology and metabolism. 26(4)
We compared the pharmacokinetic exposure, efficacy, safety and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARThis was a randomized, open-label, parallel-group, substudy of the phase 3 GEMELLI M trial performed in three In
Autor:
Bhaswati Mukherjee, Suzanne Pierre, Edward Franek, Viral N. Shah, Karita Sadeharju, Karin Wernicke-Panten
Publikováno v:
Diabetes Therapy
Introduction The biosimilar SAR341402 insulin aspart (SAR-Asp) was compared to its originator NovoLog®/NovoRapid® insulin aspart (NN-Asp) in terms of efficacy, safety, and immunogenicity, in adults with type 1 or type 2 diabetes switching from diff